This week's research shows that combining several targeted drugs — including ones that block scarring signals in the lungs — may keep lung function significantly more stable than current single-drug treatments.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week, the IPF research database grew to nearly 2,500 studies and over 820 clinical trials (studies testing treatments in real patients). Researchers continue looking hard at what causes lung scarring (when healthy lung tissue is replaced by stiff scar tissue) and how to slow it down. Most of the active work is coming from international teams, with strong contributions from Russian and Chinese researchers.
An AI system tested thousands of drug combinations and found a promising seven-drug mix. The best result kept FVC (a measure of how much air your lungs can hold and push out) at 94.7% — that is close to normal, which would be a major win for IPF patients who typically see that number drop steadily over time. The combination included drugs that block different scarring pathways at once, like cutting off a fire from multiple sides.
One question to ask your lung doctor at your next visit: 'Are there any clinical trials near me testing combination therapies for IPF, and would I be a good candidate to join one?'